Breast Cancer Sessions: Highlights from SABCS 2022 with Sara Tolaney, Paolo Tarantino & Sarah Sammons
The San Antonio Breast Cancer Symposium (SABCS) 2022 took place on the 6-10th of December 2022 in San Antonio, TX. Leading experts in breast cancer came together to hear the latest clinical trial data and discuss how to improve care for patients with breast cancer.
In this podcast, we hear from S…
The Breast Cancer Sessions: Highlights from ASCO 2021
VJOncology has assembled an international panel of leading breast cancer experts to discuss the latest advances and data from the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
In this podcast, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, is joine…
S2 Episode 3: Recent Changes in the Management of Metastatic HER2-Positive Breast Cancer
Drs Kathy Miller and Sara Tolaney discuss changes in the management of first-line metastatic HER2-positive disease and the DESTINY-Breast09 trial results.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002984. The topics and discuss…
Trastuzumab deruxtecan (T-DXd) + Pertuzumab FDA Approval in Adv HER2 Breast Cancer: DESTINY-Breast09
In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed…
Episode 43: The ASCENT-04 Trial in TNBC With Sara Tolaney
Dr. Sara Tolaney of the Dana-Farber Cancer Institute joined the show to share her insights on the ASCENT-04 trial recently published in NEJM. This is an RCT in triple-negative breast cancer. Sara led this study and as the lead author, she puts its results in context - this is a must-listen episode…
Breast Cancer Research Poised to Change Practice From ASCO25
Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast canc…
ADCs in Breast Cancer: Sequencing, Resistance, and Managing Toxicity
Drs. Hope Rugo and Sara Tolaney discuss the promise of antibody-drug conjugates (ADCs) in the treatment of breast cancer, highlighting key trials that shed light on matching the right ADC to the right patient in the right setting. They also explore how combinations and sequencing of ADCs can augme…
Sacituzumab +/- Pembrolizumab FDA Approval in Triple Negative Breast Cancer: ASCENT-03 / ASCENT-04
In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approvals for sacituzumab govitecan in frontline settings for metastatic triple-negative breast cancer. Joined by Dr. Sara Tolaney, a breast medical oncologist from the Dana-Farber Cancer Institute, we discussed th…
New First-Line Treatment: Metastatic Triple-Negative Breast Cancer with Dr. Sara Tolaney
This episode is sponsored by Gilead Sciences. Gilead had no involvement or input in the podcast content. Gilead is working to transform how cancer is treated. We are innovating with next-generation therapies, combinations, and technologies to deliver improved outcomes for people with cancer. From …
ASCO 2026 Highlights Panel Discussion
In this episode of Breast Cancer Insights, Harold Burstein, MD, PhD, speaks with Dana-Farber breast cancer experts Sara Tolaney, MD, MPH; Nancy Lin, MD; Erica Mayer, MD, MPH; and Jennifer Ligibel, MD, about important breast cancer research presented at the 2026 ASCO Annual Meeting.
The experts dis…
מנוע חיפוש PODCAST
אתה יכול להשתמש באתר שלנו כדי לחפש3,825,883פודקאסטים ופודקאסטים195,955,146לפי אנשים, מקומות או נושאים.
השקעה בידע מניבה את התשואה הטובה ביותר, ולכן אני מאזין לפודקאסטים.
‐ Benjamin "Llamacorn" Franklin
